7 Things to Know About Icotyde (Icotrokinra), an Oral Option for Plaque Psoriasis

Plaque psoriasis has several systemic treatment options, and most of the newer, more targeted ones are injectable. Icotyde (icotrokinra), approved by the FDA in March 2026, changes that. It's the first oral drug to target the IL-23 pathway, and patients are likely to start asking about it as a needle-free alternative to their current biologic or as a step up from topicals.

Here's what to know about how it works, what the trial data show, and how to counsel patients who start it.

1. It's the first oral medication to target IL-23

Icotrokinra is an IL-23 receptor antagonist. IL-23 is a cytokine that drives the Th17 inflammatory pathway behind plaque psoriasis. Icotrokinra binds the IL-23 receptor and blocks that signal from getting through.

Other drugs in this class, like Skyrizi (risankizumab) and Stelara (ustekinumab), are monoclonal antibodies given by injection. Icotrokinra is the first in the class available as a pill, which may suit patients with needle aversion or those looking for a more convenient regimen.

2. In clinical trials, most patients saw clear or almost clear skin

Icotyde's approval is based on the ICONIC program: four phase 3 trials in roughly 2,500 adults and adolescents with moderate-to-severe plaque psoriasis. In the pivotal placebo-controlled trial, ICONIC-LEAD, patients treated with icotrokinra 200 mg daily achieved by week 16:

• PASI 90 (90% skin clearance): 50%, versus 4% on placebo

• IGA 0/1 (clear or almost clear): 65%, versus 8% on placebo

• Completely clear skin (PASI 100): 27%, versus under 1% on placebo

Response kept building after week 16. By week 24, PASI 90 rates rose to 65% and IGA 0/1 to 74%, with 40% of patients reaching completely clear skin (PASI 100).

3. Administration is the main thing to get right

Icotrokinra is a peptide, and peptides are hard for the gut to absorb. That's why dosing comes with strict instructions: one 200 mg tablet, taken right after waking, on an empty stomach, with water only. Patients then need to wait at least 30 minutes before eating or drinking anything else.

This isn't a minor detail. A high-fat meal taken too close to the dose cuts drug exposure by 43%. Patients who can't reliably follow the medication instructions may not get full benefit from it, which is worth discussing before you prescribe it.

Tablets should be swallowed whole. For patients who have trouble swallowing pills, the tablet can be dispersed in a cup of water and taken within 15 minutes.

4. There are age and weight requirements

Icotyde is approved for people with moderate-to-severe plaque psoriasis as follows:

• Adults and adolescents ages 12 years and older 

• Weigh at least 40 kg (88 lb) 

• Candidates for systemic therapy or phototherapy

In the adolescent subgroup of ICONIC-LEAD, response rates were at least as good as in adults.

5. It’s generally well tolerated

The safety profile through week 16 tracked closely with placebo. The most common side effects were headache, nausea, cough, fungal infections, and fatigue — all mild and in the low single digits.

Icotrokinra is broken down through normal peptide metabolism rather than the CYP system, so it doesn't meaningfully interact with other medications.

6. Screen for TB and avoid live vaccines

Serious infections in clinical trials were uncommon. Since icotrokinra suppresses part of the immune response, though, consider evaluating for tuberculosis (TB) before starting. Use your clinical judgment, and monitor for signs of active TB during treatment. Hold the drug for anyone with a clinically significant active infection until it resolves.

It’s important for patients to avoid live vaccines, including MMR, nasal flu, rotavirus, varicella, and yellow fever. Because icotrokinra dampens part of the immune response, a live vaccine's weakened virus could cause more illness than intended. Bring patients up to date on age-appropriate vaccines before starting, and avoid live vaccines while they're on treatment. Inactivated vaccines, including the standard flu shot, are unaffected.

7. Cost is likely to be a barrier

Cost and access are likely to factor into your treatment discussion. Icotyde is available only as a brand-name medication, with a cash price over $8,000 for 30 tablets. 

• A manufacturer copay card can bring the cost as low as $0 per month for commercially insured patients. Most plans will require prior authorization.

• There may be additional assistance through the manufacturer for those without insurance or with government-sponsored plans.

Why trust our experts?

Written by:

Farzon A. Nahvi, MD

Farzon Nahvi, MD, is an emergency medicine physician and author of “Code Gray: Death, Life, and Uncertainty in the ER.” He works at Concord Hospital in Concord, New Hampshire, and teaches at the Geisel School of Medicine at Dartmouth.

Edited by:

Mandy Armitage, MD

Mandy Armitage, MD, has combined clinical medicine with her passion for education and content development for many years. She is co-executive director at Nonclinical Physicians Network and has served as medical director for the health technology companies HealthLoop (now Get Well) and Doximity.

Reviewed by:

Maria Robinson, MD, MBA

Maria Robinson, MD, MBA, is a board-certified dermatologist and dermatopathologist who has practiced dermatology and dermatopathology for over 10 years across private practice, academic, and telehealth settings. She is a fellow of the American Academy of Dermatology and the American Society of Dermatopathology.

Our editorial standards

Meet our experts